alexa On A Possible Mechanism Of Tumor Conversion Induced By Bacterial Membranotoxins
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th World Congress on Cancer Science & Therapy
October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

T Gogichadze and G Gogichadze
Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.035
As it has been found, toxins of different origin, like different carcinogenic chemical substances, irradiation and viruses can, at different doses , show in vitro diametrically opposite cytopathic effects (cytodestruction, fusogenecity), which will be correspondingly reflected in the clinical picture ? beginning at general intoxication and ending with tumor growth. It has not been finally determined but gives a serious cause to expect the same ability and action on the part of some toxins of hemolytic action and generally of membranotoxins of different tropism. Thus, completely different clinical presentations ? infection processes, intoxications, necroses, and tumors - correlate with the diametrically opposed cytopathic effects in vitro induced by toxins, viruses and other agents of different origin. Based on the above, infectious and carcinogenic processes can, irrespective of the principal difference between them (cytodestruction in one case and cytoproliferation in the other), be induced by the same agent: A bacterial membranotoxin, mycotoxin, (e.g., aflatoxin), any infectious or oncogenic virus, etc. Such double, diametrically opposed cytopathic processes developed in somatic cells by membranotoxins of different tropism (including hemolysins) must be apparently conditioned by: 1) different toxic doses; 2) different rigidity of plasma membrans of stem cells proper (e.g., erythrocytes, leucocytes, etc.), and, most important, 3) the so-called perforation degree, or pores of different size and number formed on the plasma membrane. At the same time, based on the karyogamic theory of carcinogenesis, the initial target for any carcinogens are determinants of cellular membranes, whereas any agent or effect inducing fusogenicity shall be regarded as a potential carcinogen ? or fusogenicity of somatic cells might lead to the formation of first a precancerous and then a tumor cell. As rigidity of leucocyte?s membranes is higher, it is possible that during destruction of erythrocytes (or immature cells of erythroid line) by hemolytic membranotoxins reversible damages of plasma membranes (pores of definite size and number) can be formed in leucocytes (or in other type of plasma membranes? cells of higher rigidity as compared with erythrocytes), which can promote the process of adhesion of somatic cells, leading further to the process of fusion in somatic cells and the formation of first precancerous and then cancer cell. Thus, some bacterial membranotoxins of different tropism are capable, as a result of damages of the plasma membrane of the target cell of various degree (perforations, lysis), of inducing both infectious processes as well as the formation of first precancerous and then cancer cell.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version